May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Topical Non–Steroidal Anti–Inflammatory (NSAID) And Orbital Floor Steroids In The Treatment Of Pseudophakic Cystoid Macular Edema
Author Affiliations & Notes
  • A.R. Watts
    Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom
  • R.M. Bhola
    Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom
  • A.–L. Murphy
    Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom
  • T.K. Chan
    Ophthalmology, Royal Hallamshire Hospital, Sheffield, United Kingdom
  • Footnotes
    Commercial Relationships  A.R. Watts, None; R.M. Bhola, None; A. Murphy, None; T.K. Chan, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 293. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.R. Watts, R.M. Bhola, A.–L. Murphy, T.K. Chan; Topical Non–Steroidal Anti–Inflammatory (NSAID) And Orbital Floor Steroids In The Treatment Of Pseudophakic Cystoid Macular Edema . Invest. Ophthalmol. Vis. Sci. 2004;45(13):293.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To report our experience of a combination of topical non–steroidal anti–inflammatory (NSAID) and orbital floor steroids for the treatment of Pseudophakic Cystoid Macular Edema Methods: A prospective study of consecutive patients presenting between October 2002– April 2003 (seven months), with pseudophakic cystoid macular edema (CMO). All patient were on Ketorolac four times a day and had orbital floor as an adjuvant. If there was no clinical improvement in one month, the orbital floor injections were repeated. Patients were followed for six months or until resolution of symptoms or clinical improvement of pseudophakic CMO. Results: Twelve patients entered into the study. Mean age of 75 (60–85). Onset of symptoms was between 5 and 19 weeks post operatively. Ten patients presented with symptoms and the optician referred 2 patients who were asymptomatic. There were 2 cases of vitreous loss. Two patients had a history of diabetes and one patient had a history of CMO in the other eye. Three (25%) patients required a second orbital floor injection. Ten (83%) patients had an improvement in Snellen visual acuity. Nine (75%) patients had an improvement in symptoms. There were no complications from the procedure. Conclusions: Orbital floor steroids are an effective adjunct to the treatment of CMO.

Keywords: cataract • macula/fovea • treatment outcomes of cataract surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×